None

Ohtuvayre (Ensifentrine) - Ensifentrine is a novel drug designed to treat chronic obstructive pulmonary disease (COPD) in adults with selective dual phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) inhibition. It is administered by inhalation, allowing the drug to act directly on the lungs to exert its therapeutic effect. As a retinoic acid analogue, Ohtuvayre is highly selective in its inhibitory effect on PDE3 and is more than 3,000 times more potent than PDE4. This property allows Ohtuvayre to act as both a bronchodilator and an anti-inflammatory, thus showing good potential in the treatment of COPD.

As early asin October 2015, clinical trials in chronic obstructive pulmonary disease and asthma using RPL-554 (the predecessor of Ohtuvayre) administered through a nebulizer have begun. As research progresses, Ohtuvayre gradually reveals its unique efficacy and safety. In June 2024, the U.S. Food and Drug Administration (FDA) officially approved Ohtuvayre’s inhaled product for the treatment of chronic obstructive pulmonary disease in adults. This approval marks the launch of Ohtuvayre as an innovative drug, which means that patients can obtain treatment in a more effective way.

The mechanism of action of Ohtuvayre is mainly reflected in inducing bronchodilation and reducing COPD-related inflammatory responses. Specifically, inhibition of PDE3 promotes the relaxation of bronchial smooth muscle, while inhibition of PDE4 reduces airway inflammation. This dual mechanism gives exefantine significant advantages in improving patients' respiratory function, relieving symptoms, and improving quality of life.

Reference materials:https://en.wikipedia.org/wiki/Ensifentrine